Clinical trial NCT06414434: BTX-A51 in Patients With Liposarcoma
Official title: A Pilot Study of BTX-A51 in Patients With Metastatic and/or Recurrent Liposarcomas Characterized by MDM2 Amplifications
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Liposarcoma
Recurrent Liposarcoma
Metastatic Liposarcoma
Unresectable Liposarcoma
MDM2 Gene Amplification
Keywords: Liposarcoma
Recurrent Liposarcoma
Metastatic Liposarcoma
Unresectable Liposarcoma
MDM2 Gene Amplification
Lead sponsor: Dana-Farber Cancer Institute
Sponsor class: OTHER
Collaborators: name: Edgewood Oncology Inc.
First posted: 2024-05-16
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is testing if the recommended dose of BTX-A51 is safe and tolerable in participants with liposarcoma.

The name of the study drug used in this research study is:

-BTX-A51 (a type of kinase inhibitor)

Detailed description: This is a single arm, pilot study assessing the safety and preliminary exploration of BTX-A51 in participants with metastatic and/or recurrent liposarcomas characterized by Murine Double Minute Clone 2 (MDM2) amplifications. BTX-A51 works in a different way from currently approved therapies used to treat liposarcoma by blocking proteins called CK1α and CDK9.

The U.S. Food and Drug Administration (FDA) has not approved BTX-A51 as a treatment for Liposarcoma.

The research study procedures include screening for eligibility, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, or Positron Emission Tomography (PET) scans, blood tests, and tumor biopsies.

Participants will receive study treatment for as long as there are no serious side effects, and disease does not get worse. Participants will be followed for 1 year after the last dose of BTX-A51.

It is expected that about 12 people will take part in this research study.

Edgewood Oncology is supporting this research study by providing the study drug.

Eligibility criteria: Inclusion Criteria:

* Study participants must have histologically-confirmed metastatic and/or recurrent liposarcoma (limited to the subtypes of well-differentiated and/or dedifferentiated liposarcoma, which are associated with MDM2 amplifications).
* ECOG performance status ≤2
* Adequate organ and marrow function as defined by the following metrics resulted within 7 days of study enrollment:

  * WBC \>3000/mm3
  * Platelets \>75,000μl
  * ANC \>1500μl
  * Hgb \>9g/dl
  * Creatinine \<1.5 x ULN or measured CrCl of \>60ml/m2/1.73 m2
  * Total bilirubin \<2 x ULN
  * AST/ALT \<3 x ULN
* Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non- nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as

  ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam. See Section 11 (Measurement of Effect) for the evaluation of measurable disease.
* Patients must have recovered from toxicity related to prior therapy to grade \<=1 (defined by CTCAE v5.0) (except alopecia and neuropathy, or immunotherapy related hypothyroidism)
* As the effect of this study drug on the developing human fetus is not known, women of child-bearing potential and men must agree to use at least 2 methods of contraception (abstinence; hormonal or barrier method of birth control) for the study and at least 2 months after completion.
* Female patient of childbearing potential has a negative serum pregnancy test within 7 days of study enrollment.
* Ability to understand and the willingness to sign a written informed consent document.
* Age ≥18 years
* Patients must have completed all prior anti-cancer treatment for liposarcoma, including radiation, ≥ 14 days prior to registration.

Exclusion Criteria:

* Patient with current evidence of active and uncontrolled infection, NYHA Class III-IV CHF, documented Child's class B-C cirrhosis, or uncontrolled medical disease which in the opinion of the investigator or the sponsor could compromise safety and/or assessment of efficacy.
* Active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV); subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative PCR result before enrollment; those who are PCR positive will be excluded.
* Major surgical procedure or open surgical biopsy within 28 days of first dose of study drug
* Active central nervous system (CNS) disease involvement, or prior history of NCI CTCAE Grade ≥3 drug-related CNS toxicity. Subject with known CNS metastases that are treated and stable (without evidence of CNS toxicity) and are not requiring systemic steroids are allowed to be enrolled.
* Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
* Myocardial infarction within 12 months of screening
* Use of any other concurrent investigational agents or anticancer agents, excluding hormonal therapy for breast or prostate cancer
* Pregnant women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BTX- A51, breastfeeding should be discontinued if the mother is treated with BTX-A51.
* Inability to swallow pills or inadequate GI absorption in the opinion of the treating investigator.

Primary outcomes:
measure: Number of participants with adverse events, with laboratory abnormalities, with dose modifications, delays, interruptions, or premature discontinuation of BTX-A51 due to an adverse event
timeFrame: All AEs will be recorded from the time the subject signs informed consent until 30 days after the last dose of study BTX-A51.
Secondary outcomes:
measure: Overall Response Rate (ORR)
timeFrame: ORR expected to be observed up to 3 years
measure: 1-year Progression-Free Survival (PFS) Rate
timeFrame: 1 year
measure: 1-year Overall Survival (OS)
timeFrame: 1 year
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women&#39;s Hospital
state: Massachusetts
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
Study officials:
affiliation: Dana-Farber Cancer Institute
name: Michael Wagner, MD
role: PRINCIPAL_INVESTIGATOR
References: